New York, Feb 4, 2026, 2:47 PM EST — Regular session
- Boston Scientific’s stock dropped roughly 15% following a miss on electrophysiology sales versus Wall Street expectations.
- Analysts raised new concerns about two key growth areas: electrophysiology and Watchman stroke-prevention devices.
- Investors are turning their attention to demand trends and the upcoming Watchman “CHAMPION” trial data, which is set to be highlighted at the ACC.26 meeting in late March.
Boston Scientific shares dropped sharply on Wednesday, falling roughly 15% to $77.83 following a quarterly sales report that fell short of expectations in its electrophysiology segment.
This move is significant because electrophysiology—key devices for minimally invasive heart rhythm treatments—has been central to Boston Scientific’s growth story. Missing expectations in that segment quickly saps confidence. The stock tumbled as much as 17% earlier, marking its sharpest one-day drop in over 25 years, according to Reuters.
Boston Scientific’s decline stood out amid a calmer broader market: the SPDR S&P 500 ETF slipped roughly 0.5%, and the iShares U.S. Medical Devices ETF dropped about 1%.
Sales in the electrophysiology segment hit $890 million in Q4, falling short of the $933 million consensus estimate from RBC analysts, Reuters reports.
“Their worries were not misplaced,” Citi analyst Joanne Wuensch said in a note Reuters cited. J.P. Morgan added that investors now have cause to doubt the outlook for the company’s two main growth engines. Reuters
Watchman device sales, which aid stroke prevention in certain atrial fibrillation cases, fell roughly 1% short of expectations, driven mainly by softer U.S. demand, at least three analysts told Reuters.
Management dismissed the notion that the quarter signaled a shift in momentum. CEO Michael Mahoney told analysts he was “really pleased” with 35% organic growth in electrophysiology and noted the company anticipates beating the roughly 15% electrophysiology market growth rate in 2026. (Organic growth excludes currency and deal impacts.) Reuters
Boston Scientific posted quarterly sales around $5.29 billion, with adjusted earnings hitting 80 cents per share, roughly matching forecasts, Reuters reported.
Boston Scientific’s forward guidance took the hit. The company projects first-quarter organic revenue growth between 8.5% and 10%, with adjusted EPS in the range of $0.78 to $0.80. Full-year adjusted EPS is expected to land between $3.43 and $3.49. CFO Jonathan Monson noted the Q1 outlook factors in about a 200-basis-point tailwind from foreign exchange, but also includes setbacks from discontinuing its ACURATE aortic valve systems and a temporary product recall impacting some sizes of its AXIOS device.
The company highlighted pipeline advances alongside its results, noting U.S. FDA approval and CE marking for its FARAPOINT pulsed field ablation catheter. It also kicked off an electrophysiology trial linked to its mapping technology.
The risk remains clear: if U.S. demand for electrophysiology and Watchman falters — or rivals gain ground as the market gets crowded — the “prove it” phase might drag into midyear. Guidance alone may fall short of resetting expectations. Reuters
Investors are now focused on clinical data and what it might signal for Watchman demand. Company leaders plan to unveil CHAMPION results at the American College of Cardiology’s ACC.26 meeting, set for March 28–30 in New Orleans.
